CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: The treatment with lovastatin and imatinib enhanced cytotoxicity of imatinib in cell lines as well as CD34+ chronic myelogenous leukaemia (CML) cells derived from patients diagnosed with different disease stages (Glodkowska-Mrowka et al., 2014).